Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Antagonism of secreted PCSK9 increases low density lipoprotein receptor expression in HepG2 cells.

The Journal of biological chemistry - 17 Apr 2009

McNutt Markey C, Kwon Hyock Joo, Chen Chiyuan, Chen Justin R, Horton Jay D, Lagace Thomas A

Abstract excerpt

PCSK9 is a secreted protein that degrades low density lipoprotein receptors (LDLRs) in liver by binding to the epidermal growth factor-like repeat A (EGF-A) domain of the LDLR. It is not known whether PCSK9 causes degradation of LDLRs within the secretory pathway or following secretion and reuptake via endocytosis. Here we show that a mutation in the LDLR EGF-A domain associated with familial...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hypercholesterolemia
Share to Molecular Conformation

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Proprotein Convertase 9

Share to Proprotein Convertases

Share to Protein Binding

Share to Receptors, LDL

Share to Recombinant Fusion Proteins

Share to Serine Endopeptidases

Source

Open in PubMed Open full text

Identifiers

PMID: 19224862
DOI: 10.1074/jbc.M808802200
PMCID: PMC2667743

Genes

PCSK9
LDLR
EGF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Antagonism of secreted PCSK9 increases low density lipoprotein receptor expression in HepG2 cells.PMID 19224862Read ↗

Degradation of LDLR protein mediated by 'gain of function' PCSK9 mutants in normal and ARH cells.Semantic proximity Read ↗

Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice.Semantic proximity Read ↗

The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol.Semantic proximity Read ↗

PCSK9: a key modulator of cardiovascular health.Semantic proximity Read ↗

Secreted PCSK9 promotes LDL receptor degradation independently of proteolytic activity.Semantic proximity Read ↗

Novel loss-of-function PCSK9 variant is associated with low plasma LDL cholesterol in a French-Canadian family and with impaired processing and secretion in cell culture.Semantic proximity Read ↗

Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells.Semantic proximity Read ↗

[PCSK9: Structure and function. PCSK9 and low-density lipoprotein receptor. Mutations and their effects].Semantic proximity Read ↗

Wild-type PCSK9 inhibits LDL clearance but does not affect apoB-containing lipoprotein production in mouse and cultured cells.Semantic proximity Read ↗

Internalized PCSK9 dissociates from recycling LDL receptors in PCSK9-resistant SV-589 fibroblasts.Semantic proximity Read ↗

Proprotein convertase subtilisin/kexin type 9 (PCSK9): lessons learned from patients with hypercholesterolemia.Semantic proximity Read ↗

Mutation S462P in the PCSK9 gene reduces secretion of mutant PCSK9 without affecting the autocatalytic cleavage.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.